Novartis just placed a $1.7B Alzheimer’s bet on a “boring” but decisive problem: BBB delivery. If only ~0.1% of IV antibodies reach the brain, “brain shuttles” could be the next moat. Full feature: https://biotech.industryexaminer.com/novartis-alzheimers-brain-shuttle-blood-brain-barrier/
#Biotech #Alzheimers #DrugDelivery #Neuroscience #TechNews








